INDIAN pharmaceutical firm Sun Pharma has announced the acquisition of Tokyo-based Pola Pharma with the aim of helping Sun build its dermatology business.
Pola Pharma has R&D facilities and two manufacturing plants for topical products and injectables, with annual revenue of about US$108m and a net loss of US$7m for the year to 31 Dec 2017.
Sun Pharmaceuticals is paying about $1m for the 100% stake.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Nov 18
